Investigating the efficacy of supplementation with a proprietary dairy powder in supporting muscle recovery following exercise-induced muscle damage in healthy individuals

Not Applicable

• Conditions: Muscle damage; Musculoskeletal - Normal musculoskeletal and cartilage development and function

• Registration Number: ACTRN12623000303640
• Lead Sponsor: Dr Jocelyn Eason

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-03-17
• Last Update Posted: 27 March 2023

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Healthy males and females who are not involved in any comprehensive exercise training regime and can complete the physical requirements of the exercises (determined from the familiarisation day) will be selected for this study. Participants will be required to complete a health questionnaire and provide written consent for this study.

Exclusion Criteria

Participants will be excluded if they are unwilling or unable to provide informed written consent or comply with the study procedures. Participants will also be excluded if they (i) have known hypersensitivity or intolerance to dairy, (ii) smokers, (iii) have health conditions that impair their ability to perform the exercises or may be aggravated by the exercises in this study (e.g. injury, hernia, back or joint pain, cardiovascular and breathing problems), (iv) have a Sports Index score of 4.5 or greater as assessed by a Baecke habitual physical activity questionnaire and (iv) are unable to perform the exercises to the standard required by the trial coordinator during the familiarisation session.

In addition, participants will also be excluded if they have the following health conditions: (i) blood borne diseases (e.g. hepatitis), (ii) clinically diagnosed with hypertension (high/low blood pressure) and history of fainting due to low blood pressure, (iii) recent bacterial or viral illness (2-3 weeks) or (iv) are taking medication that impact on blood clotting: warfarin, hearing and non-steroidal anti-inflammatory drugs (NSAIDS).

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Subjective measures of muscle soreness[Participants will be asked to complete a short-from McGill pain questionnaire and give a soreness score before and immediately after the bench-stepping exercise on exercise trial days. These same assessments for pain will also be measured 24, 48, 72 and 96 hours post exercise prior to muscle function assessments.];Composite measures of muscle function parameters will include absolute and average peak torque from five maximal isometric, eccentric and concentric quadriceps contractions[These assessments will be conducted before and immediately after the bench-stepping exercise on exercise trial days. Muscle function will also be measured 24, 48, 72 and 96 hours post exercise trial days.]